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Abstract
The 2016 HIV Diagnostics Conference, held in Atlanta, Georgia, was attended by public health 
officials, laboratorians, HIV testing program managers, surveillance coordinators and industry 
representatives. The conference addressed test performance data, the implementation of new 
testing algorithms, quality assurance, and the application of new tests in a variety of settings. With 
regard to the recommended Centers for Disease Control and Prevention/Association of Public 
Health Laboratories HIV laboratory testing algorithm, the conference featured performance data, 
implementation challenges such as a lack of test options for the second and third steps, as well as 
data needs for new tests that may be used as part of the algorithm. There are delays when nucleic 
acid testing is needed with the algorithm. Novel tests such as point of care nucleic acid tests are 
needed on the U.S. market to readily identify acute infection. Multiplex tests are being developed 
which allow for the simultaneous detection of multiple pathogens. CDC staff highlighted new 
guidance for testing in non-clinical settings. Innovative approaches to linking testing and care in 
some settings have led to identification of early infections, improved receipt of test results and 
expedited initiation of therapy. Work continues to optimize testing so that infections are accurately 
identified as early as possible and time to treatment is minimized to improve health outcomes and 
prevent transmission.
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1. Introduction
The 2016 HIV Diagnostics Conference, which occurred March 21–24, 2016, in Atlanta, 
Georgia, was convened by the Centers for Disease Control and Prevention (CDC), the 
Association of Public Health Laboratories (APHL), the American Sexual Health Association 
and the American Sexually Transmitted Diseases Association. It was attended by public 
health officials, laboratorians, HIV testing program managers, surveillance coordinators and 
industry representatives. This unique confluence of subject matter experts involved in every 
aspect of HIV testing fosters the development and use of new HIV testing technology in the 
United States. The conference offers a unique opportunity for persons involved in HIV 
testing to become familiar with test performance data, the implementation of new testing 
algorithms, quality assurance, and the application of new tests in a variety of settings. 
Testing is the gateway to treatment, so, fittingly, attendees emphasized the need to use 
accurate diagnostic tests and to decrease time to treatment for infected persons to improve 
health outcomes and prevent infections [1]. This report describes highlights of the 
conference from the perspectives of co-authors who participated.
Opening night presentations addressed diagnostic terminology and performance measures. 
There is movement toward describing the analytes an assay detects and away from using 
“generation” terms (e.g., antigen/antibody immunoassay instead of fourth-generation assay) 
[2]. There was a discussion on how to evaluate HIV test performance that included the 
impact on specificity of maximizing sensitivity [3]. If the penalty for missing a case is high 
(i.e., the disease is fatal, treatment exists or it spreads easily), a test cut-off should be set to 
maximize true positives, which may increase the number of false positives. When prevalence 
is low, positive screening test results are often false positive (i.e., low positive predictive 
value). Further, methods to calculate algorithm performance were discussed. Food and Drug 
Administration (FDA) staff provided an overview of HIV test regulations and the 
components of a package insert [4].
2. HIV laboratory testing algorithm
The 2014 laboratory testing algorithm recommended by CDC and APHL was designed to 
improve the detection of acute HIV-1 infections, reduce the time to testing completion, and 
accurately diagnose HIV-2 [5]. An APHL survey indicates that 55% of public health 
laboratories used the algorithm in 2014 [6]. The algorithm performed as expected. Early 
infection detection is similar for different laboratory-based antigen/antibody tests, and is 
better than for IgM-sensitive tests [7]. The likelihood of detecting acute infections depends 
on the population undergoing testing and the frequency of testing. A large metropolitan 
medical system demonstrated the algorithm’s ability to detect acute infections [8]. Data on 
the algorithm’s impact on turnaround time and testing costs can be found in two papers in 
this issue: “Real-world Performance of the New US HIV Testing Algorithm in Medical 
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Settings” and “Comparison of Turn-Around Time and Total Cost of HIV Testing Before and 
After Implementation of the 2014 CDC/APHL Laboratory Testing Algorithm for Diagnosis 
of HIV Infection”.
A roundtable session addressed algorithm implementation issues [9]. Some attendees 
expressed interest in using the Determine HIV–1/2 Ag/Ab Combo (Orgenics Ltd., Israel, 
Determine) rapid test instead of a laboratory based antigen/antibody test as the initial test in 
the algorithm. Laboratorians from low prevalence states described sharing supplemental 
antibody testing by conducting it at a central laboratory, a strategy which may decrease cost 
but likely increases turnaround time relative to testing in the original laboratory. Others 
wanted to proceed directly to nucleic acid tests (NAT) after a reactive screening test, and to 
conduct supplemental antibody tests only when the NAT is negative. Considering the 
currently available NATs, this may increase cost, including up-front costs associated with 
validation if the laboratory chooses to use a viral load test.
3. Nucleic acid testing
The laboratory testing algorithm provides timely results for antibody positive specimens, 
particularly when supplemental testing is conducted in the same laboratory [10]. However, 
delays may occur when nucleic acid testing is needed. Many laboratories do not perform 
NATs because they are expensive, technically challenging, or needed too infrequently. To 
compound the issue, only one NAT, a qualitative HIV-1 RNA assay, is approved for 
diagnostic use in the United States. If a laboratory uses a viral load test as the NAT in the 
algorithm, it must be ordered by a physician unless the laboratory has conducted an 
appropriate validation study to modify use of the test for diagnosing HIV-1 infection. 
Specimens used to initiate the laboratory algorithm may have insufficient volume or be 
inappropriate for NAT, so retrieval of a follow-up specimen may be necessary. This is 
problematic because clinicians should rapidly distinguish acute infections from antigen/
antibody immunoassay false positive tests [8].
Conference participants inquired whether manufacturers of HIV viral load tests will seek an 
FDA claim to change the intended use statement of the tests to include diagnosis as has 
occurred for at least one hepatitis C viral load test. They also asked whether an HIV viral 
load test used for diagnostic purposes would be a lab developed test (LDT) as updated LDT 
guidance has not been finalized by FDA. Over thirty public health laboratories use a shared 
services model to obtain NAT as part of the laboratory algorithm, though the time from 
specimen collection to NAT results is approximately 10 days, which does not include the 
provision of results to the individual tested [11]. Accessible, less costly NATs are needed so 
that test result provision and linkage to care and partner services can be expedited.
Alternative quantitative and qualitative options for simplified NAT are on the horizon, but 
the timeline for their availability on the U.S. market is unclear [2]. Conference attendees 
expressed concern that like antigen/antibody tests that entered the U.S. market years after 
other countries, there will be a considerable delay in the availability of simplified NAT due 
to regulatory hurdles the manufacturers will have to overcome [12]. This prompted a 
discussion on the appropriate pathway to engage and collaborate with FDA to ease 
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regulatory requirements so that tests such as these, which are necessary for identifying acute 
infections and monitoring viral suppression expeditiously, can enter the U.S. market as soon 
as possible.
4. Impact of three new tests on the laboratory algorithm
Two screening tests (Determine, and BioPlex 2200 HIV Ag-Ab assay (Bio-Rad 
Laboratories, Hercules, CA, BioPlex)) and one supplemental antibody test (Geenius HIV-1/2 
Supplemental Assay, Bio-Rad Laboratories, Redmond, WA, Geenius) which were recently 
FDA approved may impact the laboratory algorithm [13]. The Determine rapid test provides 
separate results for HIV-1 p24 antigen and HIV-1/2 antibody. It detects infection earlier than 
IgM/IgG sensitive assays when used with plasma, but after antigen/antibody laboratory 
assays that use larger sample volume and have more complex technology [14]. Its use is not 
currently recommended in the laboratory algorithm. In order for CDC/APHL to make 
recommendations for the use of Determine in laboratory settings, published data are needed 
on the performance of (1) Determine with serum, plasma and whole blood when it is used as 
the initial test in the algorithm and (2) antibody supplemental test and HIV-1 nucleic acid 
test results when the p24 antigen component of the test is reactive. Some attendees indicated 
that Determine may be useful as a screening test in the laboratory algorithm in small volume 
laboratories, and in clinical laboratories needing immediate results. In a conference follow-
up survey, approximately one-third of respondents indicated that they would use Determine 
with plasma in the laboratory algorithm if it were given as an alternative.
BioPlex, a multiplex bead immunoassay, gives separate results for HIV-1 antibodies, HIV-2 
antibodies, and HIV-1 p24 antigen. It detects early infection at approximately the same time 
as other laboratory antigen/antibody tests and is highly sensitive for established infections 
[7]. Published data are needed on (1) its performance in combination with Geenius and 
HIV-1 NAT (2) the results of HIV-1 NAT and HIV-2 NAT testing if Bioplex is HIV-2 Ab 
reactive and Geenius is not HIV-2 positive (3) the results of supplemental antibody testing 
and HIV-1 nucleic acid testing after BioPlex results where only HIV-1 p24 antigen is 
reactive.
Geenius is the only FDA approved supplemental HIV-1/HIV-2 differentiation test remaining 
on the market. An article in this issue, “Comparative Performance of the Geenius HIV-1/
HIV-2 Supplemental Test in Florida’s Public Health Testing Population”, reports on its 
performance in an evaluation at the Florida Bureau of Public Health Laboratories. In a study 
using stored serum/plasma specimens from a high risk population, 99.8% of HIV-1 Western 
blot positive specimens were detected by Geenius and there were no false positive algorithm 
results (i.e., reactive antigen/antibody assay and Geenius results in an uninfected specimen) 
[7]. Geenius sensitivity and specificity was similar to that of the previous differentiation test 
on the market, Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad Laboratories, Redmond, WA, 
Multispot) [7]. Specimens that were HIV-2 positive using Multispot generated a variety of 
Geenius results: HIV-2 positive, HIV-2 positive with HIV-1 cross reactivity, HIV untypable, 
HIV-2 indeterminate and HIV negative [15]. The test generates three results that Multispot 
did not: HIV-2 positive with HIV-1 cross reactivity, HIV-2 indeterminate, and HIV 
indeterminate. Specimens with results that are HIV-2 positive with HIV-1 cross reactivity 
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should be considered HIV-2 positive for reporting. HIV-2 indeterminate test results for 
samples from persons without HIV-2 risk factors should be confirmed by retesting with 
Geenius using a new cassette [16]. An HIV indeterminate result occurs in specimens with 
bands to both HIV-1 and HIV-2 detected that do not meet the criteria for HIV-1 positive or 
HIV-2 positive.
Several instances of repeat HIV-2 indeterminate results were reported during the conference. 
They were reported for specimens from persons with acute HIV-1 infection, false positive 
antigen/antibody or IgM/IgG immunoassay results, and HIV-2 infected specimens [7,15,17]. 
The gp36 band was only detected in HIV-2 indeterminate results arising from true HIV-2 
infections, while gp140 was the only band present for the HIV-2 indeterminate results from 
specimens with false positive antigen/antibody results. One solution to improve accuracy 
would be for the manufacturer to alter the internal proprietary algorithm used for defining 
HIV-2 reactivity.
Published data are needed on Geenius performance and cost as well as this algorithm 
pathway: following a reactive laboratory antigen/antibody assay result, if a specimen 
repeatedly produces HIV-2 indeterminate results or HIV indeterminate results, conduct an 
HIV-1 NAT because some specimens with these results are acutely infected with HIV-1. If 
HIV-1 is detected by NAT, this result indicates acute HIV-1 infection, and the person should 
be referred for immediate medical care. If the HIV-1 NAT is negative, conduct a validated 
supplemental HIV-2 test or repeat testing in 2–4 weeks. There are no HIV-2 nucleic acid 
tests approved by the FDA for diagnosis. Two presentations addressed the performance of 
new laboratory developed HIV-2 NATs, one on the detection and quantification of HIV-2 
proviral DNA using droplet digital PCR and another on an HIV-2 total nucleic acid 
qualitative assay using the Abbott m2000 platform [18,19].
5. Alternatives to the recommended laboratory algorithm
Two studies examined the signal to cut-off ratio for the ARCHITECT HIV Ag/Ab Combo 
(Abbott Laboratories, Abbott Park, IL, ARCHITECT). The first provided data on repeating 
the ARCHITECT in duplicate only when the initial run had a signal to cut-off ratio of less 
than 10 rather than on all initially reactive samples in order to improve turnaround time and 
decrease cost [20]. This approach is not FDA-approved, so validation is required. The 
second indicated that a high signal to cut-off ratio predicted HIV infection but a low ratio 
does not rule-out acute HIV infection, and requires nucleic acid testing for resolution [8]. In 
a third study, the U.S. Army used a separate antigen/antibody assay after a reactive antigen/
antibody assay in its HIV Diagnostic Algorithm to improve the positive predictive value of 
the initial result and decrease the amount of supplemental testing needed [21].
6. Surveillance
HIV testing data are used by surveillance units to describe disease burden, monitor progress 
toward prevention goals, and identify HIV-diagnosed individuals who are not in care so that 
they can be linked with a provider [22,23]. Challenges to obtaining accurate, complete data 
include incomplete reporting of all tests performed for an individual, health care provider 
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confusion with ordering tests and health department/provider confusion with laboratory 
report interpretation. The surveillance issues associated with implementation of the 
laboratory testing algorithm were the topic of a roundtable discussion led by staff from four 
state health departments [24]. The roundtable brought additional hurdles to light such as the 
lack of awareness by some laboratories that negative supplemental antibody tests should be 
followed with a nucleic acid test, inconsistent use of LOINCs (Logical Observation 
Identifiers Names and Codes) or the use of proprietary coding by reporting laboratories, the 
frequent need to link results from multiple testing laboratories for a given specimen to reach 
a final algorithm result, and the fact that many cases do not represent newly diagnosed 
persons. The need to educate laboratorians and clinicians on the laboratory testing algorithm 
emerged repeatedly. New York Department of Health staff presented on a web-based toolkit 
and webcast they created to assist laboratory directors with overcoming potential barriers to 
implementing the algorithm [25]. This approach combined web-based access to resources on 
testing recommendations, regulations, reporting guidelines and reimbursement along with 
practical information from laboratorians who had implemented the algorithm.
7. CLIA-waived testing
A conference session was dedicated to testing that occurs outside of traditional laboratory 
settings with CLIA-waived rapid tests. CDC staff presented 2016 non-clinical testing 
guidance which features practical considerations for HIV testing providers and gives 
information on programmatic issues and updates that impact HIV testing service delivery. It 
complements “Planning and Implementing HIV Testing and Linkage Programs in Non-
clinical Settings”, which includes the benefits and drawbacks for different testing algorithms 
that can be used in non-clinical settings, a topic of interest at the conference. Conference 
attendees discussed whether a person with a single positive rapid test should be referred to 
care, and the consensus was that it depends on community prevalence. Testing guidance 
documents can be found along with other HIV testing resources at www.cdc.gov/hiv/
testing/.
A consultant from National Alliance of State and Territorial AIDS Directors (NASTAD) 
described key points from their 2015 survey of health department HIV testing programs 
[26]. The survey indicated that oral fluid testing has decreased substantially since 2009. In 
addition, only a third of respondents conduct third-party billing for health department 
delivered HIV testing services. Finally, most health departments do not plan to support self-
testing activities.
Citing their self-testing study, CDC authors pointed out that without in-person training, the 
majority of internet-recruited men who have sex with men who reported their results online 
successfully conducted rapid testing on themselves and collected dried blood spots [27]. 
Self-testing may allow persons who would not otherwise test to do so, though methods for 
successful linkage of persons with HIV infection must be examined.
A new CDC study conducted by the University of Washing-ton, Diagnostic Evaluation To 
Expand Critical Testing Technologies (DETECT), will assess the performance of new rapid 
tests, evaluate seroconversion sensitivity via serial follow-up with whole blood, oral fluid 
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and plasma and examine risk characteristics of those identified in seroconversion [28]. Also, 
evidence was presented that when the INSTI HIV-1/HIV-2 Rapid Antibody test (bioLytical 
Laboratories Inc., Richmond, BC, Canada) is used with simulated whole blood, it performs 
similarly to plasma for detection of early HIV-1 infection [29].
8. Linkage to care
In addition to test performance, there were presentations on the real-world application of 
testing and its impact on linkage to HIV care. When using the laboratory algorithm, some 
persons may not get their results or results may be delayed. Part of the impetus for beginning 
a statewide rapid testing algorithm program in New Jersey was the fact that 25% of persons 
did not receive their Western blot test results after a reactive rapid test [30]. After expanding 
the program, most people screened by a rapid test receive verification and linkage within 2 
business days. The testing program has reduced the time to linkage through the use of local 
linkage to care collaboratives and 74% of clients are linked to HIV care within 30 days. It 
embeds HIV Prevention Patient Navigators in large HIV clinics to initiate, monitor and 
follow-up with newly engaged clients.
A roundtable session was held on improving the impact of HIV testing through better 
linkage and timely viral suppression [31]. Almost 79% of persons diagnosed with HIV are 
virally suppressed in King County, Washington, a number which is much higher than the 
national average. This is attributed, in part, to increased testing frequency, the use of 
sensitive tests, and high levels of treatment coverage. San Francisco General Hospital 
researchers described the provision of same-day, observed antiretroviral treatment to 
improve virologic suppression in newly diagnosed patients.
9. Special testing circumstances
During a session on special testing circumstances, Indiana State Department of Health staff 
described the evolution of testing strategies to improve sensitivity during an HIV and 
hepatitis C virus (HCV) outbreak in their state associated with injection drug use [32]. A 
separate presentation addressed the use of HIV-1 sequence data to infer transmission 
networks and inform public health action [33].
Staff from the US Military HIV Research Program presented on the impact of early 
treatment on subsequent disease markers. Treatment at Fiebig stage I blocked subsequent 
emergence of anti-HIV biomarkers commonly targeted by HIV tests while treatment at stage 
II delayed or decreased these serologic markers, and treatment at stages III and IV delayed 
or decreased seroreactivity [34]. Blood Systems Research Institute staff described the need 
for assays that allow for monitoring an individual’s latent HIV reservoir as we move into an 
era of early treatment initiation and targeted cure research [35].
A roundtable addressed the collection and use of dried blood spots (DBS), and highlighted 
the ease of collection and transportation of specimens, and their utility for diagnosis, 
monitoring and surveillance [36]. DBS can be used for HIV-1 nucleic acid testing, though 
the threshold for detection is lower than for plasma, in part due to lower input sample 
volume. DBS can also be used for drug resistance genotyping. The only U.S. diagnostic HIV 
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tests approved for use with DBS are an IgG-sensitive immunoassay and Western blot. A 
paper in this issue addresses the use of DBS: “Evaluation of dried blood spot (DBS) 
protocols with Bio-Rad GS HIV Combo Ag/Ab EIA and GeeniusTM HIV 1/2 Supplemental 
Assay”.
10. New tests for diagnosis, clinical staging, and surveillance
Based on the NASTAD survey, opportunities for testing for multiple pathogens are being 
missed: only 17% of respondents conducted HCV testing in all settings where HIV testing 
was provided. To test for HIV and syphilis in a hospital emergency department, separate 
rapid tests for each pathogen were employed at the point of care by dedicated non-
emergency department staff [37]. Rapid tests are in development that detect multiple 
analytes. Chembio Diagnostics’ DPP HIV-Syphilis Multiplex Rapid Test detects antibodies 
for HIV-1/HIV-2 and T. pallidum [38]. BioLytical Laboratories developed a 60 s multiplex 
test that detects the same analytes [39]. Though the manufacturers report promising 
performance of these new tests, additional evaluations are needed.
A session on expanded applications of testing highlighted ongoing work to improve 
surveillance tools to determine rates of recent infection at the population level. CDC staff 
described how the switch to a BioRad Avidity assay from the BED assay and updated 
estimates of assay parameters were being implemented and how these changes affect 
population incidence estimates [40]. New assays designed to identify recent infection are in 
the developmental pipeline, but data are needed to determine the benefits of these new 
technologies [41,42]. An updated system was presented that uses routinely collected clinical 
data to approximate an individual’s stage of infection [43]. Finally, the Consortium for the 
Evaluation and Performance of HIV Incidence Assays described the potential repurposing of 
some assays to produce surveillance estimates for recent HIV infection [44].
11. Conclusion
The conference highlighted novel HIV testing technology, but accurate tests alone are not 
sufficient for improving health. Testing processes must be streamlined so that time to 
treatment is reduced. With respect to the recommended HIV laboratory testing algorithm, 
alternative tests for the second and third steps are needed that will allow laboratories to 
conduct all testing in the same facility. Novel technologies such as simplified nucleic acid 
tests can identify acute infections rapidly and may be easier to implement in a variety of 
settings than existing options, but hurdles exist to get tests such as these to market or to 
modify existing tests. Data are needed on their use in conjunction with other tests. 
Opportunities are expanding to synchronize testing for multiple analytes in high risk 
populations. Testing and linkage strategies must be examined in a variety of settings to 
ensure that HIV and related pathogens are identified and treated as early as possible.
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